Next Article in Journal
Vaccine-Induced Humoral and Cellular Response to SARS-CoV-2 in Multiple Sclerosis Patients on Ocrelizumab
Previous Article in Journal
A Similar Nonclinical Safety Evaluation of Prev(e)nar 13 in a Multi-Dose Formulation Containing the Preservative 2-Phenoxyethanol
Previous Article in Special Issue
Viral Infections in Elderly Individuals: A Comprehensive Overview of SARS-CoV-2 and Influenza Susceptibility, Pathogenesis, and Clinical Treatment Strategies
 
 
vaccines-logo
Article Menu

Article Menu

Article

Article Versions Notes

Vaccines 2025, 13(5), 487; https://doi.org/10.3390/vaccines13050487
Action Date Notes Link
article xml file uploaded 30 April 2025 10:51 CEST Original file -
article xml uploaded. 30 April 2025 10:51 CEST Update https://www.mdpi.com/2076-393X/13/5/487/xml
article pdf uploaded. 30 April 2025 10:51 CEST Version of Record https://www.mdpi.com/2076-393X/13/5/487/pdf
article html file updated 30 April 2025 10:54 CEST Original file https://www.mdpi.com/2076-393X/13/5/487/html
Back to TopTop